The (Busy!) Year in Review: The Emergence of Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension in 2025

Feb 16, 2026 | Hypertension

2) During 2025 you learned about these developments from @PamTaubMD & @edgarvlermamd 🇵🇭. You can still earn 🆓credit at https://t.co/36ZYdDsq8G. Our look back is led by #cardiometabolic expert Muthu Vaduganathan @mvaduganathan, #Cardiologist @BrighamWomens...

The Nephrology Community’s Reception of New Phase 3 Data on Aldosterone Synthase Inhibitors for Difficult-to-Control Hypertension at ESC2025

Oct 31, 2025 | Hypertension

2) You've already seen those data w/@PamTaubMD & u can still earn 🆓credit by checking out https://t.co/Jnm3I9eari. Now we take a look at those data through the eyes of our favorite #nephrology expert & prolific author, Edgar Lerma @edgarvlermamd...

New Phase 3 Data from ESC on Management of Uncontrolled or Treatment-Resistant Hypertension with an Aldosterone Synthase Inhibitor

Aug 29, 2025 | Hypertension

2) Our returning expert faculty is Pam R Taub MD @PamTaubMD, #Cardiologist & Prof Medicine @UCSDMedSchool 🇺🇸. She will be reporting & commenting on Prof Bryan Williams' @UCLH presentation of #BaxtHTN earlier today! pic.twitter.com/o6X78Cv5L2—...

The Importance to Cardiorenal Outcomes of Effective Blood Pressure Control and the Pathophysiologic Role of Aldosterone Dysregulation

May 28, 2025 | Hypertension

2) This program is intended for #HCPs & is supported by an unrestricted educational grant from AstraZeneca. Statement of accreditation & faculty disclosures at https://t.co/gvXca4G9Xm. Follow this 🧵for 0.75 hr 🆓CE/#CME credit–all delivered right here on...

Current Management of Difficult-to-Control Hypertension

Mar 25, 2025 | Hypertension

2) We are pleased to welcome a new & esteemed guest faculty member, Alta Schutte PhD @alta_schutte, Professor of Cardiovascular Medicine from @UNSWMedicine and @georgeinstitute & Past President @ISHBP pic.twitter.com/kjGVvQy9Cs— cardio-met...